Hospital Costs of Adverse Events in Patients with Metastatic Melanoma
نویسندگان
چکیده
منابع مشابه
Hospital Costs of Adverse Events in Patients with Metastatic Colorectal Cancer
Background: Monoclonal antibody treatments for metastatic colorectal cancer (mCRC) have distinct treatment-related safety profiles. This study aimed to elucidate the hospitalisation costs of adverse events (AEs) commonly associated with monoclonal antibodies when administered to patients with mCRC. Methods: This study extracted data for patients newly diagnosed with mCRC from a large US claims ...
متن کاملHospital costs associated with adverse events in gynaecological oncology
44 45 Background and objective: Treatment for gynaecological malignancies is complex and may 46 cause unintended or accidental adverse events (AE). We evaluated the costs of hospitalization 47 associated with those AEs among patients who had an abdominal or laparoscopic procedure 48 for proven or suspected gynaecological cancer at a tertiary gynaecological cancer center in 49 Australia. 50 51 M...
متن کاملHospital costs associated with adverse events in gynecological oncology.
BACKGROUND AND OBJECTIVE Treatment for gynecological malignancies is complex and may cause unintended or accidental adverse events (AE). We evaluated the costs of hospitalization associated with those AEs among patients who had an abdominal or laparoscopic procedure for proven or suspected gynecological cancer at a tertiary gynecological cancer center in Australia. METHODS Data on AEs were pr...
متن کاملEconomic burden associated with adverse events in patients with metastatic melanoma.
BACKGROUND There are currently many approved agents for the treatment of metastatic melanoma (MM), the most aggressive form of skin cancer. Treatments may include systemic therapies such as ipilimumab, dacarbazine, temozolomide, high-dose interleukin 2, interferon α, dacarbazine- or temozolomide-based combination chemotherapy/biochemotherapy, paclitaxel, paclitaxel/cisplatin, and paclitaxel/car...
متن کاملHospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment)
BACKGROUND Management of metastatic melanoma is changing rapidly following the introduction of innovative effective therapies, with consequences for the allocation of healthcare resources. The objective of this study was to assess hospitalisation costs of metastatic melanoma in France from 2011 to 2013 from the perspective of the government payer. METHODS The population studied corresponded t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2014
ISSN: 1098-3015
DOI: 10.1016/j.jval.2014.03.477